Introduction
The management of patients with chronic viral hepatitis or 25 inflammatory bowel diseases (IBD) has been revolutionized in the last years by the introduction of highly effective treatments. The availability of potent antivirals against hepatitis B virus (HBV) and hepatitis C virus (HCV), as well as the introduction of anti-TNF biological drugs, has improved patients' 30 survival and quality of life. Although viral hepatitis and IBD do not share any common pathological pathway and thus are usually not clinically associated, it is not uncommon to find patients who are both chronically infected with HBV or HCV and have IBD, given the relatively high prevalence of these 35 diseases. As shown by several studies across Europe, the prevalence of patients with coexisting viral hepatitis and IBD usually follows the epidemiology of viral hepatitis in the single country [1, 2] . From a clinical standpoint, the management of these patients is challenging due to many reasons: drugs used 40 in the treatment of IBD may result in liver toxicity, thus leading to worsening of the coexisting liver disease; immunosuppressive regimens used to treat IBD may lead to viral reactivation which can progress to liver failure in selected cases; moreover, drug-drug interactions (DDIs) between therapies administered 45 for viral hepatitis or IBD may lead to reduced response rates or unexpected adverse events. In this review, we will analyze the most recent literature on these topics to determine the optimal management of viral hepatitis in patients with IBD in Europe. 50 
Epidemiology of HBV and HCV
Prevalence of chronic Hepatitis B in Europe ranges from 0.4-0.5% reported in Northern Europe and countries such as Spain to 3.4% and 5.6% reported in Greece and Romania, respectively, to more than 8% in the strict European neighbo rhood like Turkey [3, 4] .
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Eastern countries, including Eastern Europe, Russia, and Eastern Asia represent areas with intermediate-high HBV endemicity, with HBV prevalence ranging from 2% to more than 8% in South east Asian countries. Although new incident cases are steadily declining due to the implementation of a vaccination 60 policy for HBV in most European countries, the increase in migration from areas of high endemicity that Europe is witnessing might significantly alter the epidemiology profile of HBV in Europe in the next decade. The impact of migration can already be witnessed in countries with a historically high prevalence, such as Italy, where two different populations of chronically HBV-infected patients exist. The first consists mostly of men in their 50-60s that were infected locally decades ago, and usually present with mild moderate liver disease. The second group is mostly constituted by migrants who are of younger age, are around 0.3% increasing to 1-2% in Italy and Greece. Chronic HCV is also highly prevalent in Eastern Europe (Romania reporting 3.2% prevalence) and in the Southern Italian regions, 80 where HCV prevalence is more than 6-8% [3, [6] [7] [8] . Most HCV cases in Europe can be traced to two global pandemias: the first one occurred from 1940 to 1970 and is related to iatrogenic transmission of the virus through contaminated blood products, while the second one followed the spreading of 85 intravenous-drug use in the 1970 s and 1980 s [9] . The local epidemiology of HCV in one country can thus be estimated by understanding which pandemia influenced the spread of HCV locally. In Southern Europe, where most HCV cases were infected due to iatrogenic spread, patients are older and the 90 burden of HCV has already peaked and is now declining due to death for liver or not liver-related causes of the original cohort of patients. In Northern Europe on the other hand where nearly 75% of HCV cases can be found in people who inject drugs (PWID), patients are younger and the burden of 95 the disease is still increasing and is expected to peak in the next 10-15 years [10] . Given that HBV, HCV, and IBD do not share common disease pathways, and since the risk of acquiring viral hepatitis through iatrogenic procedures is now extremely low, there is no specific reason to suspect that patients 100 with IBD should more often be chronically infected with HBV or HCV. Supporting this theory are data gathered throughout Europe that demonstrate that the prevalence of chronic HBV or HCV infection in IBD patients mimics what reported in the general population of the specific country [1, 2, [11] [12] [13] [14] [15] . Studies 105 concerning HBV and HCV prevalence in IBD patients are summarized in Table 1 .
Many studies have underlined the low prevalence of anti-HBV vaccination in IBD patients, ranging from 12% reported by a Spanish multicenter study to 23% in a single-center 110 Italian experience [1, 14] . This results both from little awareness and implementation of immunization policies by physicians and also from reduced efficacy of anti-HBV vaccination in immunocompromised patients (see paragraph 4). However, the development of nationwide HBV vaccination programs in 115 many European countries is expected to raise prevalence of HBV vaccination in the general population in the near future, starting from younger generations.
Epidemiology of IBD
In close analogy with other immune-mediated diseases, IBD 120 incidence is characterized by a north-south and a urban-rural gradient [16] ; additionally, most epidemiological studies have reported a higher prevalence of IBD in Western with respect to Eastern countries. Even if the reasons underlying these geographical trends have not been elucidated, differences in diet, sun exposure, and intestinal microbiome have been implicated [17] . Notably, of the 5 million people worldwide affected by IBD, it is estimated that 1.5 million reside in the United States and nearly 3 million in Europe [18] , where a west-east gradient has been reported. However, these data should be 130 interpreted with caution as they are limited by the paucity of high-quality population-based studies available in Eastern and developing countries. Recent studies estimate an annual ulcerative colitis (UC) incidence ranging from 0 to 19.2 per 100,000 and from 0.6 to 24. 3 
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[20]. A more in-depth analysis of disease subtypes led to the demonstration that UC is more prevalent than CD in Europe and in Asia, while the opposite is true for Australia; in the United States, CD and UC are equally distributed [19] . Only scant data are available regarding IBD diffusion in other countries: in Brazil, an incidence of 4.5 and 3.5 per 100,000 individuals has been reported for UC and CD, respectively [21]; in the Punjab state of Northern India, an incidence of 6 per 100,000 has been reported for UC [22] .
As IBD prevalence is due to rise in the next years due to 155 compounding prevalence (i.e. an exponential rise in prevalence due to cumulative addition of incident cases in a chronic disease that has a young age of onset and low mortality), several studies suggest that IBD incidence also is on the rise in both Western and Eastern countries. No clear explanations have been provided for the rising incidence of IBD worldwide, even if it has been hypothesized that it may result from a combination of advances in health care infrastructure (e.g. easier and quicker access to endoscopy) and environmental factors. The latter explanation is further corroborated by the 165 significantly increased IBD incidence in migrants with respect to that observed in their countries of origin [23]. 
Clinical challenges: interplay between IBD and viral hepatitis
The natural history of HBV or HCV infection in the setting of 170 IBD is poorly understood and studied, due to the scarcity of prospective data and presence of many confounding factors: indeed, exposure to multiple and sequential immunosuppressive treatments for IBD management could theoretically determine a more rapid progression of HBV or HCV-related liver 175 disease. On the other hand, presence of a immune-mediated disease like IBD was considered a relative contraindication to Interferon (IFN)-based treatment of HBV or HCV in the past, due to the increased risk of IBD exacerbation, so that IBD patients were less likely to receive antiviral treatment for 180 HCV in the IFN-based era, thus providing a potential bias in determining a worse outcome of IBD-HCV patients with respect to the HCV general population. In the HBV setting, administration of nucleoside or nucleotide analog s (NUCs), to treat HBV-related chronic hepatitis or prevent HBV reactivation 185 during immunosuppressive therapy, impairs the possibility to evaluate the natural history of HBV infection in IBD patients.
The largest patient series providing information about longterm outcome of liver disease in IBD patients comes from a Spanish multicenter study (REPENTINA study), including 25 It is now well known that immunosuppressive treatment confers an increased risk of viral reactivation in HBV infection: 205 this is due to the fact that humoral and, especially, cellular immune responses are crucial for the control of HBV replication [25] . Indeed, tumor necrosis factor-α (TNF-α) and IFN-γ, targeted by immunosuppressants and anti-TNF drugs are key cytokines involved in HBV clearance from infected hepato-210 cytes, through elimination of cytosolic HBV replicative intermediates and nuclear covalently close circular DNA (cccDNA). Enhanced viral replication during the administration of immunosuppressive regimens results in hepatitis reactivation after the discontinuation of immunosuppressive drugs when 215 immune reconstitution occurs and infected hepatocytes are targeted by the immune system. As a consequence, hepatitis reactivation typically occurs after immunosuppressive treatment is withdrawn [ Reinforcing the concept that AQ3 more pronounced immunosuppression is associated with higher risk of reactivation is the growing number of case reports of HBV reactivations during treatment with anti-TNF drugs, that are characterized by dif-250 ferent mechanism of action with respect to standard immunosuppressants [12, [29] [30] [31] [32] [33] [34] . Taken together, these case reports account for eight HBV reactivations occurring during Infliximab (IFX)-based treatment: CD was the underlying IBD in all cases, and the vast majority of patients received combined treatment with almost another immunosuppressive drug (corticosteroids and/or AZA). Timing for reactivation ranged from 1 IFX infusion to 24-month treatment course; severity of HBV reactivation varied from mild aminotransferase increase to fulminant hepatitis and two out of eight patients tion [24] .
Another key factor differentiating the risk of HBV reactivation in the IBD setting from patients receiving immunosuppressants for oncologic diseases is the prolonged treatment duration ; while chemotherapy is administered for short and repeated cycles, treatment of IBD patients is prolonged long term, although the level of immunosuppression achieved is lower than classical chemotherapy. The importance of prolonged treatment duration has been confirmed by a retrospective Korean study, evaluating 134 HBsAg-positive IBD patients treated with different kinds of immunosuppressive treatments (corticosteroids, IFX, and AZA/6-mercaptopurine): liver dysfunction occurred in 23 patients (17.2%), prolonged (>3 months) immunosuppression representing the strongest risk factor [35] .
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No cases of HBV reactivation with the other anti-TNF drug Adalimumab (ADA) in IBD patients have been described till now; however, HBV reactivations are reported in two patients receiving ADA as anti-TNF treatment for rheumatological diseases, resulting in severe hepatic failure and death in one case [36] [37] [38] .
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In HBsAg-negative anti-HBc-positive patients, that is, patients with previous HBV contact, risk of HBV reactivation due to immunosuppressive treatment seems negligible. Literature reports only four cases of HBV reactivation in anti-HBc-positive patients receiving anti-TNF treatment, efficiently managed 295 through anti-HBV treatment administration, except for one patient developing severe hepatic failure [38] [39] [40] [41] . On the other hand, many case series in the rheumatological setting confirm absence of HBV reactivation in more than 200 HBsAgnegative patients receiving different anti-TNF drugs [42] .
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Concerning HCV-infected patients, administration of immunosuppressive treatment was historically thought to worsen the outcome of liver disease, this hypothesis being reinforced by the accelerated fibrosis progression in HCV patients receiving immunosuppressants for liver transplantation and by the observation 305 that steroid treatment could increase viral load [43, 44] . However, these concepts have not been confirmed in the setting of IBD patients, where immunosuppression does not seem to significantly affect liver disease progression [24] . Conversely, modulation of TNF-α pathways has been claimed even beneficial in HCV 310 patients, as TNF-α is involved in liver inflammation and hepatocyte apoptosis, and upregulation of TNF pathways was thought to affect non response to IFN-based treatments [45, 46] . Indeed, a randomized controlled trial in HCV-infected patients, investigating the role of the anti-TNF Etanercept in combination with IFN 315 and Ribavirin for anti-HCV treatment, showed a significant reduction in aminotransferase values and a higher HCV-RNA decline in the Etanercept arm [47] .
Few data exist about outcome of immunosuppressive therapy for IBD in HCV patients, however presence of HCV infection does 320 not seem to represent a major concern in treatment of IBD patients: in the REPENTINA study, 8/51 (16%) HCV patients treated for IBD developed a 1.5-2-fold increase in aminotransferase values or a significant increase in HCV viral load, however these alterations were not clinically relevant [24] . Similarly, Morisco and colleagues 325 reported mild elevation of transaminases and viral load in 1 out of 10 HCV patients treated for IBD [41] and two more reports about 4 CD patients treated with IFX showed no significant change in liver function tests and serum HCV-RNA during a maximum of 12 months treatment course [48, 49] . Apart from IBD patients, 330 many reports concerning anti-TNF treatment for rheumatologic diseases show no significant safety concern in HCV patients in more than 153 patients [42, 50] . Finally, methotrexate and AZA have also been shown safe in HCV-infected patients, both in treating rheumatologic diseases and in liver transplanted patients [51] . 
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management of HBV infection in IBD patients is performed only with these latter drugs [52] . Active carriers are defined as HBsAg-positive, HBeAg-or anti-HBeAg-positive patients, with persistently or fluctuating elevated aminotransferases and active viral replication (HBV-DNA > 2000 IU/ml): this condition, which is defined chronic hepatitis, is associated with progressive liver disease and requires HBV treatment independently from administration of immunosuppressive therapy for IBD. Third-generation NUCs Entecavir or Tenofovir are the recommended drugs, due to the potent anti-360 viral activity, resulting in rapid viral suppression, and high barrier to resistance [53] . As shown by registration trials and real-life studies, these drugs achieve HBV-DNA negativity in more than 99% patients with none or negligible resistance rates long term [54, 55] and, consequently, have optimal profile also to manage 365 long-term immunosuppressive treatments required for IBD. Safety and efficacy of NUCs for treating HBV infection in IBD patients have been confirmed in case series and study cohorts [55] . Treatment duration in active carriers is dictated by the need of treating HBV chronic hepatitis per se, independently from immunosuppressive therapy for IBD; at present, NUCs administration is intended life long, although some studies are concentrating on the possibility to stop NUCs administration after many years of efficient viral suppression or after achievement of HBsAg negativity.
Inactive carriers are defined as HBsAg-positive, anti-HBepositive patients with persistently normal aminotransferases and HBV-DNA < 2000 IU/ml: these patients have no evidence of progressive liver disease and do not require antiviral treatment in the HBV general population. On the contrary, as discussed above, risk of HBV reactivation in HBsAg-positive IBD patients undergoing immunosuppressive therapy ranges from 20% to more than 30% and requires prophylaxis of HBV reactivation by NUCs administration. Risk of HBV reactivation depends on the type of immunosuppressive agent administered: anti-TNF drugs, integrin inhibitors, and a course of prednisone ≤ 10 mg/day for at least 4 weeks are considered at moderate risk, so that prophylaxis is mandatory [56] . There has been much debate about the possibility of using a less potent NUC like Lamivudine to prevent HBV reactivation in inactive carriers, who typically display low levels of HBV replication and, consequently, could be managed by a less expensive drug than third-generation NUCs Entecavir and Tenofovir. However, the prolonged administration of immunosuppression for IBD advises against using a drug with low barrier to resistance as Lamivudine, as some cases of resistance to Lamivudine pr ophylaxis are described [33], so that today third-generation NUCs are the preferred drugs for prophylaxis in HBV inactive carriers [52] . Absence of correct prophylaxis strategies and use of weak drugs like Lamivudine could justify 400 bad outcomes reported by studies concentrating on HBV reactivation in IBD patients in past years. HBV prophylaxis should be carried on for the entire duration of immunosuppressive treatment and prolonged after the discontinuation of immunosuppressants due to the fact that the risk of HBV 405 reactivation is higher when immune reconstitution occurs [26, 53, 56, 57] . There is currently much debate about the recommended duration of HBV prophylaxis after discontinuation of immunosuppressive therapy, as at least 6 -12 months have been suggested, depending also on the type of immu-410 nosuppressive agent administered [26, 56] .
To simplify and summarize management of HBsAg-positive patients who need immunosuppressive treatment for concurrent IBD, administration of third-generation NUCs Entecavir or Tenofovir is recommended to treat HBV (active carriers) or as a 415 prophylaxis for HBV reactivation (inactive carriers); the duration depends on HBV status, as active carriers need to be treated life long, whereas prophylaxis in inactive carriers can be discontinued 6-12 months after the cessation of immunosuppressive treatment.
HBsAg Anti-HBV vaccination is recommended in all IBD patients with negative HBV serology: in patients receiving concurrent treatment with immunosuppressants, the standard schedule 440 for HBV vaccination has been shown ineffective in conferring adequate seroprotection [58] . Importantly, adequate serological response
AQ4
to anti-HBs vaccination has been recently reported in healthy subjects exposed to the α4β7 integrin inhibitor vedolizumab, as to suggest that the gut selectivity of this monoclonal antibody may be associated with reduced immunosuppressive effects following exposure to parenteral vaccines [59] . Nonetheless, an accelerated schedule AQ5 with double-dose recombinant HBsAg (40 mcg at 0-1 2 months) has been advocated as the best vaccination strategy for IBD patients: in the REPENTINA-3 multicenter study, administration of accelerated double-dose rHBsAg provided seroprotection (anti-HBs title 10-100 mIU/mL) in 110/254 (43%) IBD patients and effective vaccination ( anti-HBs > 100 mIU/mL) in 67/254 (27%) [60] . Another study in 241 IBD patients showed higher 455 efficacy rates, respectively, 59% for seroprotection and 42% for vaccination [61] . Serological response to vaccination should be checked after 1 or 2 months, and revaccination is recommended in patients failing to achieve adequate response after a first vaccine course. As seroprotection loss can occur 460 long term, regular monitoring of anti-HBs titles should be performed yearly or every 2 years, and a unique booster dose is recommended to restore anti-HBs title > 100 mIU/ mL, especially in patients undergoing anti-TNF treatment [52] .
Given the relative safety of immunosuppressive drugs for 465 IBD in HCV-infected patients, current recommendations do not contraindicate immunomodulators in HCV patients, although the decision should be based on the severity of both IBD and liver disease. Regular monitoring of liver function tests and aminotransferases every 3 months is suggested; no safety data 470 exist about treatment of patients suffering from liver dysfunction with immunomodulators and especially anti-TNF drugs, so that they are currently not recommended in decompensated cirrhosis [52] . Current guidelines on management of HBV or HCV-infected 475 IBD patients receiving immunosuppressive treatment are summarized in Table 2 . In HCV patients, concurrent IBD represented in the past a relative contraindication to IFN-based treatment due to the risk of IBD exacerbation. This was true especially for CD, where 480 administration of IFN was associated with CD onset in previously asymptomatic patients [62, 63] or exacerbations of known CD, although an Austrian study on 11 CD patients receiving PegIFN and Ribavirin treatment demonstrated that, in 6 patients exhibiting CD reactivation, the disease could be 485 efficiently managed by optimizing immunosuppressive treatment with steroids [64] . In addition, antiviral treatment in CD patients showed comparable efficacy with respect to the general HCV population. On the other hand, IFN had been initially claimed as a potential adjuvant treatment to induce UC remis-490 sion, however a randomized-controlled trial in 60 UC patients failed to confirm this hypothesis, although it demonstrated that PegIFN administration in UC patients did not translate in increased adverse events [65] . A review of existing literature concluded that IFN-based treatment could be feasible in 495 patients with stable IBD remission [66] .
This notwithstanding, the recent development of directacting antiviral drugs (DAAs) to cure HCV infection paved the way to safely achieve viral eradication in IBD patients. Indeed, the elimination of IFN from the recommended standard of 500 care treatment has allowed to extend eligibility to antiviral therapy also in patients suffering from immune-mediated diseases like IBD [67] . While efficacy of DAAs in registration trials and real-life studies exceeds 95% across nearly all genotypes in the HCV general population, more data are currently 505 needed in special populations like IBD patients, although there is no theoretical reason to suspect a reduced DAAs efficacy in this patient population. Concerning safety, the only topic to address are the potential DDIs between DAAs and immunosuppressive drugs, especially anti-TNF.
5. Drug-drug interactions
A pharmacokinetic drug interaction occurs when one drug (perpetrator) alters the concentrations of a second drug (victim). Pharmacokinetic interactions at the level of drug metabolism represent an important site for DDIs. Cytochrome P450 515 iso enzymes are responsible for the metabolism of many drugs.
In particular, CYP3A is responsible for the oxidative metabolism of more than 40% of the drugs in clinical use [68] . Many DDIs are attributable to CYP450 enzyme inhibition or induction. There are limited pharmacokinetic DDI studies between 520 HCV DAA and drugs used in the treatment of IBD. An understanding of drug disposition for drugs used in the treatment of IBD can guide in predicting potential DDIs in the absence of pharmacokinetic interaction studies. Steroids are frequently used systemically or topically in inducing remission in IBD.
525 Systemic absorption of steroids may occur with topical rectal suppositories or foam enemas, but is rarely complete. Prednisolone, the active metabolite of prednisone is formed in vivo by 11β-hydroxydehydrogenase after oral administration. Prednisolone is subsequently metabolize d through a 530 CYP3A4-mediated pathway [69] . Drugs that inhibit CYP3A will result in increased systemic exposure of prednisolone, with an increased risk of steroid-related side effects. Prednisone is also a substrate of P-glycoprotein (P-gp) [70, 71] .
Azathioprine is the pro drug of 6-mercaptopurine, which is 535 further metabolize d to natural purines by inosine monophosphate dehydrogenase (IMPDH) [72] . Methotrexate is a substrate of the OATP1B1 and breast cancer resistance protein (BCRP) drug transporters, and is predominantly eliminated unchanged by the kidneys with minimal metabolism [73, 74] .
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Inhibitors of the OATP1B1 or BCRP drug transporters may therefore increase methotrexate concentrations with potential toxicity.
Ledipasvir-sofosbuvir
Ledipasvir (90 mg) and sofosbuvir (400 mg) are co-formulated 545 in a fixed dose combination that is administered once daily. Neither sofosbuvir nor ledipasvir are metabolize d by CYP450 enzymes. Ledipasvir is primarily excreted in bile as unchanged part drug. Sofosbuvir is a P-gp substrate, and ledipasvir is a weak inhibitor of P-gp and BCRP [75] . Co administration of 550 ledipasvir-sofosbuvir has not been studie d with prednisone, azathioprine, or methotrexate. However, a clinically significant interaction with prednisolone azathioprine/6-mercaptopurine, or methotrexate is unlikely based on their metabolic pathways.
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Simeprevir-sofosbuvir
Simeprevir (an NS4/4A protease inhibitor) is metabolize d by CYP3A and is a mild inhibitor of intestinal CYP3A and CYP1A2 [76] . No interaction is expected between simeprevir and azathioprine (6-mercaptopurine) or methotrexate.
Co administration of simeprevir with prednisone may result in increased systemic exposure of prednisolone due to inhibition of intestinal CYP3A4 be simeprevir. While no dose adjustment of prednisone is required, monitoring for steroid side effects is recommended.
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Daclatasvir-sofosbuvir
Daclatsavir (an NS5A inhibitor) is a substrate of CYP3A4 and P-gp, and an inhibitor of OATP1B1, P-gp and BCRP [77] . While co administration has not been studied, no clinically significant interaction is expected between daclatasvir and azathioprine 570 (6-mercaptopurine) or prednisone. A potential interaction exists between daclatasvir and methotrexate. The administration of daclatasvir in a patient receiving methotrexate may result in increased concentrations of methotrexate due to daclatasvir-mediated inhibition of the OATP1B1 drug transpor-575 ter. H ematological blood monitoring is required with this combination.
Ritonavir-boosted paritaprevir, ombitasvir plus dasabuvir (P/r/O + D)
Paritaprevir is metabolize d by CYP3A and is given with lowdose ritonavir, a potent CYP3A inhibitor to optimize paritaprevir exposure. This combination has the potential for numerous ritonavir-related DDIs. Ritonavir is a potent hepatic and intestinal CYP3A inhibitor, and also inhibits P-gp and BCRP.
Paritaprevir is an inhibitor of OATP-1B1/1B3, P-gp and BCRP.
585 Dasabuvir is an inhibitor of BCRP and P-gp [78] [79] [80] [81] [82] .
There is no overlap in the metabolic pathways of P/r/O + D and azathioprine/6-mercaptopurine. Therefore, no drug interactions are expected. Monitoring of h ematological blood counts would be prudent if P/r/O + D is administered with 590 methotrexate due to BCRP inhibition by ritanovir, paritaprevir, and dasabuvir. Co administration of P/r/O + D with prednisone has not been studied. Prednisolone exposure may be increased due to CYP3A4 inhibition by ritonavir. Patients should be monitored for steroid-related side effects. Ribavirin is frequently administered in combination with HCV DAA in patients with cirrhosis or previous treatment experience to maximize response to therapy, and shorten treatment duration [85] . A significant potential interaction exists with 610 ribavirin and azathioprine (6-mercaptopurine). Ribavirin has an inhibitory effect on IMPDH [86] , an important enzyme in the metabolic pathway of 6-mercaptopurine. The co administration of ribavirin with azathioprine or 6-merpatopurine may result in elevated levels of 6-methylthioinosine 615 monophosphate (6-MTITP) through blockade of IMPDH activity [87] . Elevated levels of 6-MTITP have been shown to be associated with myelotoxicity (neutropenia, thrombocytopenia and/or an emia) in patients treated with azathioprine for IBD [72] . Pancytopenia and bone marrow suppression have been 620 reported in eight patients receiving pegylated IFN ribavirin concomitantly with azathioprine [87] . The combination of ribavirin with azathioprine is contraindicated in patients with high thiopurine methyltransferase (TPMT) levels, and should also ideally be avoided in patients with normal TPMT activity 625 given the risk of myelotoxicity [87] . This potential interaction exists for up to 2 months after the cessation of ribavirin therapy because of its long half-life.
Biologics for IBD
Biologics including anti-TNF-α antibodies (e.g. infliximab, adali-630 mumab) and anti-integrins (e.g. vedolizumab) have revolutionize d the management of IBD. Infliximab and vedolizumab are given as an intravenous infusion, whereas adalimumab is administered via subcutaneous injection. The elimination pathways for these agents have not been characterize d and 635 no drug interaction studies have been performed between HCV DAA and biologic agents for IBD. Clinically significant interactions would not however be expected as the biologics are not substrates of CYP450 and gut transporters.
Nucleoside analog s for hepatitis B
excreted unchanged in the urine [90, 91] . The kidneys primarily excrete tenofovir DF by both tubular filtration and active tubular secretion [92] . There is a potential for competitive inhibition for active tubular secretion if lamivudine and methotrexate are co-prescribed, which may result in increased 650 serum concentrations of either or both drugs with associated potential toxicity. This competitive inhibition for renal tubular secretion may also arise with tenofovir DF and methotrexate. This combination would require close monitoring of renal function.
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Main DDIs between HBV/HCV DAAs and IBD agents are summarized in Table 3 .
Expert commentary
IBD (CD and UC) are chronic diseases affecting the intestinal tract, characterized also by a systemic involvement due to extraintestinal manifestations. The natural course of IBD typically alternates periods of disease remission and recrudescence with reactivations displaying different degrees of severity, potentially resulting in need for surgical treatment. The long course of the disease, the specific bowel involvement resulting in discomforting symptoms, and the severe exacerbations requiring hospitalization and surgery determine a strong impairment in patients' quality of life, in terms of social, working, and also relational disability.
At present, management of these patients is complicated by a limited knowledge of precise causative and pathophysiological mechanisms, so that current treatment strategy requires administration of immunosuppressing/immunomodulating drugs in order to achieve and maintain disease remission. These drugs require careful and specialist management 675 because they are characterized by side effects both short term (i.e. steroid-induced diabetes) and long term (i.e. increased risk of malignancies), so that periodical monitoring is recommended and, in some cases, treatment is supplied only in hospital settings. In this scenario, patient comorbidities and 680 concomitant diseases have to be carefully considered before starting immunosuppressive treatments: as chronic infection with HBV or HCV affect, respectively, more than 400 and 150 million people worldwide, these liver diseases are likely to interplay with IBD according to local epidemiology in different countries.
Due to the potential risk of hepatitis reactivation during immunosuppressing therapy, current management of IBD patients requires screening for HBV and HCV markers before starting immunosuppressive treatment, in order to determine the patient's virological status and consequently the need for treating chronic hepatitis or administering adequate prophylaxis to prevent hepatitis reactivation in the HBV setting. As a consequence, this strategy is actually complex because it presumes good knowledge of different hepatitis 695 serological markers and specialist referral for HBV/HCV treatment administration or monitoring.
However, research in the field of viral hepatitis is pushing very hard and the recent development of new DAA s has paved the way for a true revolution in HCV treatment, due 700 to the high efficacy rates and, most of all, the excellent safety profile allowing to treat patients formerly contraindicated to antiviral therapy in the IFN-based era. This is particularly appealing for IBD patients, as risk for IBD reactivation with IFN excluded many patients from the possibility to receive 705 HCV therapy in the past. If widespread of DAAs will be pursed at the global level, HCV eradication will be feasible in the next decades, so that concurrent HCV infection will no longer represent a clinical problem in IBD management. In the HBV setting, on the other hand, current nucleotide/nucleoside ana-710 log s are already efficacious and safe, however they achieve only virological suppression and due to the specific HBV replication cycle, are not able to eradicate the virus (the so-called functional cure ). This is the specific research area in the HBV field at the moment, where new compounds are intended to 715 target the cccDNA replication machinery, that is also the driving force of viral reactivation during immunosuppressive treatment. If the functional cure will be achieved, also HBV will not impact IBD clinical management so far. Finally, the most important research area in the near future will be the devel-720 opment of new compounds for IBD therapy with the primary goal of achieving remission in patients failing to respond to currently available treatment options. Another primary goal will be to develop IBD drugs targeting different molecular pathways, in order to provide safer and manageable com-725 pounds with reduced need for monitoring and fewer side effects. These goals will be achieved only through a deeper insight in pathophysiological mechanisms of IBD that should be pursued by strong effort in basic research.
Conclusions and 5-year view 730
The current management of patients with chronic HBV or HCV and concomitant IBD requires precise definition of the viral disease status, viral replication levels, and disease stage. Internationally accepted guidelines which have been summarized in this paper provide an adequate tool to manage the risk 735 of HBV reactivation, HBsAg seroconversion, and concomitant chronic HCV infection. In the upcoming years, novel therapeutic strategies will be included into the therapeutic armamentarium for patients with active IBD [93] . Among these, it is presumable that a low risk of HBV or HCV reactivation will be 740 observed following administration of compounds with gutselective mechanisms of action (e.g. α4β7 integrin inhibitors) 750 eration DAAs will be optimized versions of currently available drugs, with pan-genotypic activity, optimal pharmacokinetic profile and high genetic barrier to resistance that will allow these drugs to be active also in treatment failures to first-and second-generation DAAs. Although it will be mandatory to 755 asses DDIs with these new compounds, the management of viral hepatitis C in patients with IBD is unlikely to be modified by these DAAs. On the other hand, treatment of HBV will be radically transformed in the next years by drugs that target the immune system as well as antivirals that inhibit different steps 760 of the HBV life cycle including modulation and silencing of ccc-DNA transcription. These drugs could solve the need for active prophylaxis of patients receiving immunosuppressive drugs and thus could play a major role in the management of HBV in patients with IBD.
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